Aldeyra Therapeutics reports that FDA rejects eye cancer drug

Aldeyra Therapeutics Inc has received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection) for primary vitreoretinal lymphoma (PVRL).